Page last updated: 2024-12-07

5'-adenylyl (beta,gamma-methylene)diphosphonate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5'-adenylyl (beta,gamma-methylene)diphosphonate, also known as AppCp, is a non-hydrolyzable analog of ATP. It is a synthetic compound that mimics the structure of ATP but is resistant to hydrolysis by ATPases. AppCp is commonly used as a tool in biochemistry to study the role of ATP in various biological processes, as it can bind to and activate enzymes that normally utilize ATP but cannot be broken down. For instance, AppCp is a potent inhibitor of the enzyme adenylate cyclase, which catalyzes the conversion of ATP to cyclic AMP. AppCp can also act as a substrate for protein kinases, which phosphorylate proteins using ATP. The resistance of AppCp to hydrolysis makes it a useful tool for studying the kinetics of enzymatic reactions and for investigating the mechanisms of ATP-dependent processes. AppCp is often used in combination with other experimental techniques, such as X-ray crystallography and NMR spectroscopy, to provide detailed structural and functional insights into the role of ATP in biological systems.'

5'-adenylyl (beta,gamma-methylene)diphosphonate: do not confuse with alpha,beta-methyleneadenosine 5'-triphosphate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID91532
CHEMBL ID133463
CHEBI ID40532
SCHEMBL ID2037068
MeSH IDM0046485

Synonyms (46)

Synonym
adenosine 5'-[beta,gamma-methylene]triphosphate
9h-purin-6-amine, 9-[5-o-[hydroxy[[hydroxy(phosphonomethyl)phosphinyl]oxy]phosphinyl]-.beta.-d-ribofuranosyl]-
[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]methylphosphonic acid
adenosine 5'-o-[.beta., .gamma.-methylene]-triphosphate
amp-pcp
beta,gamma-methylene atp
phosphomethylphosphonic acid adenylate ester
DB03909
1KF0
CHEBI:40532 ,
adenosine 5'-beta,gamma-mu-methylenetriphosphate
NCGC00163317-01
5'-o-(hydroxy{[hydroxy(phosphonomethyl)phosphoryl]oxy}phosphoryl)adenosine
adenosine (beta,gamma-methylene)triphosphate
3469-78-1
adenylyl(beta,gamma-methylene)diphosphonate
5'-adenylyl (beta,gamma-methylene)diphosphonate
5'-adenylic acid, monohydride with methylenebis(phosphonic acid)
l-beta,gamma-methylene adenosine 5'-triphosphate
adenosine 5'-beta,gamma-methylenetriphosphate
adenylyl methylene diphosphate
bdbm18135
chembl133463 ,
adenylylmethylenediphosphonate
atp,beta gamma-me
amppcp
({[({[(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}methyl)phosphonic acid
adenosine 5'-monophosphate, monoanhydride with (phosphonomethyl)phosphonic acid
[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methylphosphonic acid
einecs 222-435-7
bdbm50370142
l-betagamma-meatp
betagamma-methylene-adenosine 5'-triphosphate
gtpl4236
SCHEMBL2037068
5'-o-[(r)-hydroxy{[(s)-hydroxy(phosphonomethyl)phosphoryl]oxy}phosphoryl]adenosine
UFZTZBNSLXELAL-IOSLPCCCSA-N
Q27079196
HY-106723
CS-0026413
9-[5-o-(hydroxy{[hydroxy(phosphonomethyl)phosphoryl]oxy}phosphoryl)pentofuranosyl]-9h-purin-6-amine
DTXSID80956172
(((((((2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)methyl)phosphonic acid
5'-adenylyl methylenediphosphonate
5'-adenylic acid, 5'-anhydride with p,p'-methylenediphosphonic acid
AKOS040740697

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"The effects on platelet function of a 5-day course of Ticlopidine (Tcl) have been studied in two groups of volunteers receiving different dosage schedules."( The action of ticlopidine on human platelets. Studies on aggregation, secretion, calcium mobilization and membrane glycoproteins.
Hardisty, RM; Nokes, TJ; Powling, MJ, 1990
)
0.28
" Data were used to plot dose-response curves for the four test compounds."( Adenosine mediates the negative chronotropic action of adenosine 5'-triphosphate in the canine sinus node.
Menduke, H; Michelson, EL; Mitsuoka, T; Pelleg, A, 1987
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
nucleoside triphosphate analogue
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glycine--tRNA ligaseBombyx mori (domestic silkworm)Ki0.80000.80000.80000.8000AID1797699
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Phosphoglycerate KinaseSus scrofa (pig)Kd2,800.00002,800.00002,800.00002,800.0000AID977611
P2X purinoceptor 1Rattus norvegicus (Norway rat)EC50 (µMol)2.00000.05402.761310.0000AID152476
P2Y purinoceptor 1Meleagris gallopavo (turkey)EC50 (µMol)100.00000.00251.70498.0000AID150470
P2X purinoceptor 1Homo sapiens (human)EC50 (µMol)2.00000.05402.462310.0000AID152476
P2X purinoceptor 3Homo sapiens (human)EC50 (µMol)9.20000.24002.80229.2000AID150157
P2Y purinoceptor 12Rattus norvegicus (Norway rat)EC50 (µMol)100.00000.00111.09044.0000AID150495
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (36)

Processvia Protein(s)Taxonomy
monoatomic ion transportP2X purinoceptor 1Homo sapiens (human)
serotonin secretion by plateletP2X purinoceptor 1Homo sapiens (human)
regulation of vascular associated smooth muscle contractionP2X purinoceptor 1Homo sapiens (human)
apoptotic processP2X purinoceptor 1Homo sapiens (human)
signal transductionP2X purinoceptor 1Homo sapiens (human)
inseminationP2X purinoceptor 1Homo sapiens (human)
regulation of blood pressureP2X purinoceptor 1Homo sapiens (human)
neuronal action potentialP2X purinoceptor 1Homo sapiens (human)
calcium-mediated signalingP2X purinoceptor 1Homo sapiens (human)
platelet activationP2X purinoceptor 1Homo sapiens (human)
response to ATPP2X purinoceptor 1Homo sapiens (human)
synaptic transmission, glutamatergicP2X purinoceptor 1Homo sapiens (human)
purinergic nucleotide receptor signaling pathwayP2X purinoceptor 1Homo sapiens (human)
ceramide biosynthetic processP2X purinoceptor 1Homo sapiens (human)
excitatory postsynaptic potentialP2X purinoceptor 1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationP2X purinoceptor 1Homo sapiens (human)
positive regulation of calcium ion import across plasma membraneP2X purinoceptor 1Homo sapiens (human)
regulation of synaptic vesicle exocytosisP2X purinoceptor 1Homo sapiens (human)
calcium ion transmembrane transportP2X purinoceptor 1Homo sapiens (human)
response to hypoxiaP2X purinoceptor 3Homo sapiens (human)
signal transductionP2X purinoceptor 3Homo sapiens (human)
neuromuscular synaptic transmissionP2X purinoceptor 3Homo sapiens (human)
response to heatP2X purinoceptor 3Homo sapiens (human)
response to coldP2X purinoceptor 3Homo sapiens (human)
response to mechanical stimulusP2X purinoceptor 3Homo sapiens (human)
response to carbohydrateP2X purinoceptor 3Homo sapiens (human)
positive regulation of calcium ion transport into cytosolP2X purinoceptor 3Homo sapiens (human)
urinary bladder smooth muscle contractionP2X purinoceptor 3Homo sapiens (human)
peristalsisP2X purinoceptor 3Homo sapiens (human)
purinergic nucleotide receptor signaling pathwayP2X purinoceptor 3Homo sapiens (human)
regulation of synaptic plasticityP2X purinoceptor 3Homo sapiens (human)
behavioral response to painP2X purinoceptor 3Homo sapiens (human)
positive regulation of calcium-mediated signalingP2X purinoceptor 3Homo sapiens (human)
sensory perception of tasteP2X purinoceptor 3Homo sapiens (human)
establishment of localization in cellP2X purinoceptor 3Homo sapiens (human)
excitatory postsynaptic potentialP2X purinoceptor 3Homo sapiens (human)
protein homotrimerizationP2X purinoceptor 3Homo sapiens (human)
cellular response to ATPP2X purinoceptor 3Homo sapiens (human)
inorganic cation transmembrane transportP2X purinoceptor 3Homo sapiens (human)
calcium ion transmembrane transportP2X purinoceptor 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
purinergic nucleotide receptor activityP2X purinoceptor 1Homo sapiens (human)
extracellularly ATP-gated monoatomic cation channel activityP2X purinoceptor 1Homo sapiens (human)
monoatomic cation channel activityP2X purinoceptor 1Homo sapiens (human)
protein bindingP2X purinoceptor 1Homo sapiens (human)
ATP bindingP2X purinoceptor 1Homo sapiens (human)
identical protein bindingP2X purinoceptor 1Homo sapiens (human)
suramin bindingP2X purinoceptor 1Homo sapiens (human)
protein-containing complex bindingP2X purinoceptor 1Homo sapiens (human)
ligand-gated calcium channel activityP2X purinoceptor 1Homo sapiens (human)
purinergic nucleotide receptor activityP2X purinoceptor 3Homo sapiens (human)
extracellularly ATP-gated monoatomic cation channel activityP2X purinoceptor 3Homo sapiens (human)
ATP bindingP2X purinoceptor 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
plasma membraneP2X purinoceptor 1Homo sapiens (human)
external side of plasma membraneP2X purinoceptor 1Homo sapiens (human)
secretory granule membraneP2X purinoceptor 1Homo sapiens (human)
specific granule membraneP2X purinoceptor 1Homo sapiens (human)
membrane raftP2X purinoceptor 1Homo sapiens (human)
postsynaptic membraneP2X purinoceptor 1Homo sapiens (human)
presynaptic active zone membraneP2X purinoceptor 1Homo sapiens (human)
glutamatergic synapseP2X purinoceptor 1Homo sapiens (human)
protein-containing complexP2X purinoceptor 1Homo sapiens (human)
plasma membraneP2X purinoceptor 1Homo sapiens (human)
plasma membraneP2X purinoceptor 3Homo sapiens (human)
axonP2X purinoceptor 3Homo sapiens (human)
Schaffer collateral - CA1 synapseP2X purinoceptor 3Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseP2X purinoceptor 3Homo sapiens (human)
postsynapseP2X purinoceptor 3Homo sapiens (human)
receptor complexP2X purinoceptor 3Homo sapiens (human)
plasma membraneP2X purinoceptor 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID107744Inhibitory constant against rat Methionine adenosyltransferase was reported; Not determined1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Isozyme-specific enzyme inhibitors. 10. Adenosine 5'-triphosphate derivatives as substrates or inhibitors of methionine adenosyltransferases of rat normal and hepatoma tissues.
AID150495Antagonist activity against phospholipase C coupled rat P2Y purinoceptor 12 (P2Y12)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID150622Agonist activity by measuring inositol phosphate accumulation in 1321N1 human astrocytoma cells stably expressing human P2Y purinoceptor 2; No effect as either agonist or antagonist at 10 uM2002Journal of medicinal chemistry, May-09, Volume: 45, Issue:10
Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists.
AID150157The compound was evaluated for antagonist activity against recombinant rat P2X purinoceptor 3 (P2X3) at 3 uM, expressed in Xenopus oocytes2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID150338Agonist activity by measuring inositol phosphate accumulation in 1321N1 human astrocytoma cells stably expressing human P2Y purinoceptor 1; No effect as either agonist or antagonist at 10 uM2002Journal of medicinal chemistry, May-09, Volume: 45, Issue:10
Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists.
AID165257Agonist activity by measuring Purinoceptor P2Y1-promoted phospholipase C activity in turkey erythrocyte membranes; No effect as either agonist or antagonist at 10 uM2002Journal of medicinal chemistry, May-09, Volume: 45, Issue:10
Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists.
AID152476Antagonist activity against recombinant human P2X purinoceptor 1 (P2X1 )2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID107903Inhibitory constant against rat kidney Methionine adenosyltransferase II; Not determined1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Isozyme-specific enzyme inhibitors. 10. Adenosine 5'-triphosphate derivatives as substrates or inhibitors of methionine adenosyltransferases of rat normal and hepatoma tissues.
AID150470Evaluated for agonist activity against phospholipase C coupled P2Y purinoceptor 1 (P2Y1) of turkey erythrocytes2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2002Biochemistry, Jul-16, Volume: 41, Issue:28
Crystallographic and thiol-reactivity studies on the complex of pig muscle phosphoglycerate kinase with ATP analogues: correlation between nucleotide binding mode and helix flexibility.
AID1811Experimentally measured binding affinity data derived from PDB2002Biochemistry, Jul-16, Volume: 41, Issue:28
Crystallographic and thiol-reactivity studies on the complex of pig muscle phosphoglycerate kinase with ATP analogues: correlation between nucleotide binding mode and helix flexibility.
AID1797699In Vitro Enzyme Activity Assay from Article 10.1021/bi030031h: \\Thermodynamic characterization of the binding of nucleotides to glycyl-tRNA synthetase.\\2003Biochemistry, May-13, Volume: 42, Issue:18
Thermodynamic characterization of the binding of nucleotides to glycyl-tRNA synthetase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (292)

TimeframeStudies, This Drug (%)All Drugs %
pre-199073 (25.00)18.7374
1990's107 (36.64)18.2507
2000's92 (31.51)29.6817
2010's17 (5.82)24.3611
2020's3 (1.03)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.68 (24.57)
Research Supply Index5.69 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (1.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other291 (98.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]